New research 869: Memantine in primary headache

Ann Pharmacother. 2014 Aug 26. pii: 1060028014548872. [Epub ahead of print]

Memantine for the Prevention of Primary Headache Disorders.

Huang L1, Bocek M2, Jordan JK3, Sheehan AH4.

Author information

Abstract

OBJECTIVE:

To describe the current data evaluating the efficacy and safety of memantine for the prevention of primary headache disorders.

DATA SOURCES:

A literature search using MEDLINE (1966-July 2014) and EMBASE (1973-July 2014) was conducted using the search terms memantine, headache, migraine, glutamate, and NMDA. References of identified articles were reviewed for additional, relevant citations.

STUDY SELECTION AND DATA EXTRACTION:

All English-language articles dealing with the use of memantine for prevention of primary headache disorders were included.

DATA SYNTHESIS:

Data from several retrospective reports and 2 prospective clinical trials suggest that memantine may be a useful treatment option for the prevention of primary headache disorders. The majority of available literature focuses specifically on chronic migraine prevention in refractory patients who had failed multiple previous prophylactic therapies. In these patients, 10 to 20 mg of memantine daily reduced the frequency and intensity of migraine headaches and was generally well tolerated, with few adverse events. Data regarding the efficacy of memantine for other primary headache disorders such as chronic tension type and cluster headaches are limited.

CONCLUSION:

Although further studies evaluating the efficacy of memantine for prevention of primary headache disorders are warranted, memantine may be a reasonable option, used either as monotherapy or adjunctive therapy, in the refractory chronic migraine prophylaxis setting.

ATB
P.